

REFERENCES

1. Inzerillo AM, Zaidi M. Osteoporosis: Trends and intervention. *Mt Sinai J Med* 2002;69:220-31.
2. Lipschitz S. Osteoporosis: Diagnosis and treatment. *Geneeskunde* 2000;July:18-27.
3. Dequeker J, Ortner DJ, Stix AI, Cheng X-G, Brys P, Boonen S. Hip fracture and osteoporosis in a XIIIth dynasty female skeleton from Lisht, Upper Egypt. *J Bone Miner Res* 1997;12:881-8.
4. Kalu DN. Evolution in the pathogenesis of postmenopausal bone loss. [Review]. *Bone* 1995;17:135S-44S.
5. South African Medical Association: Osteoporosis Working Group. Osteoporosis clinical guideline. *S Afr Med J* 2000;90:907-44.
6. Raisz LG. Physiology and pathophysiology of bone remodeling. *Clin Chem* 1999;45:1353-8.
7. Jimi E, Nakamura I, Amano H, H, Taguchi Y, Tsurukai T, Tamura M, *et al.* Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. *Endocrinology* 1996;137:2187-90.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, *et al.* Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998;95:3597-602.
9. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burggess T, *et al.* Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998;93:165-76.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, *et al.* Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 1997;89:309-19.
11. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, *et al.* Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. *Biochem Biophys Res Commun* 1998;250:229-34.
12. Li J, Sarosi I, Yan X-Q, Morony S, Capparelli C, Tan H-L, *et al.* RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. *Proc Natl Acad Sci USA* 2000;97:1566-71.
13. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, *et al.* Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. *J Immunol* 1999;163:434-42.

14. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J Bone Miner Res* 2000;15:2-12.
15. Anderson JJB, Rondano P, Holmes A. Nutrition, life style and quality of life. Roles of diet and physical activity in the prevention of osteoporosis. [Review] *Scand J Rheumatol* 1996;25 (Suppl 103):65-74.
16. Watkins BA, Li Y, Seifert MF. Dietary omega-3 fatty acids and bone health. *Current Organic Chem* 2000;1125-44.
17. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: Highlights of the conference. *South Med J* 2001;94:569-73.
18. Haag M. Essential fatty acids and the brain. [Review]. *Can J Psychiatry* 2003;48:195-203.
19. Haag M. Polyunsaturated fatty acids: Cellular role and clinical applications (Part 2). [Review]. *The Medicine Journal (SA)* 2002;44:30-4.
20. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part I. *Urol Oncol* 2005;23:28-35.
21. Kettler DB. Can manipulation of the ratios of essential fatty acids slow the rapid rate of postmenopausal bone loss? *Altern Med Rev* 2001;6:61-77.
22. Albertazzi P, Coupland K. Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention. *Maturitas* 2002;42:13-22.
23. Kruger MC, Horrobin DF. Calcium metabolism, osteoporosis and essential fatty acids: a review. *Prog Lipid Res* 1997;36:131-51.
24. Das UN. Essential fatty acids and osteoporosis. *Nutrition* 2000;16:386-90.
25. Schlemmer CK, Coetzer H, Claassen N, Kruger MC. Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat. *Prostaglandins Leukot Essent Fatty Acids* 1999;61:381-90.
26. Van Papendorp DH, Coetzer H, Kruger MC. Biochemical profile of osteoporotic patients on essential fatty acid supplementation. *Nutr Res* 1995;15:325-34.
27. Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging Clin Exp Res* 1998;10:385-94.

28. Fernandes G, Lawrence R, Sun D. Protective role of n-3 lipids and soy protein in osteoporosis. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:361-72.
29. Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. *J Bone Miner Res* 2003;18:1206-16.
30. Kokkinos PP, Shaye R, Alam BS, Alam SQ. Dietary lipids, prostaglandin E₂ levels, and tooth movement in alveolar bone of rats. *Calcif Tissue Int* 1993;53:333-7.
31. Claassen N, Potgieter HC, Seppa M, Vermaak WJH, Coetzer H, van Papendorp DH, Kruger MC. Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks, total urinary hydroxyproline, and bone calcium content. *Bone* 1995;16:385S-92S.
32. Weiss LA, Barrett-Connor E, von Mühlen D. Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo study. *Am J Clin Nutr* 2005;81:934-8.
33. Atkinson TG, Barker HJ, Meckling-Gill KA. Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats. *Lipids* 1997;32:293-302.
34. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic effect of parathyroid hormone on bone. *Endocr Rev* 1993;14:690-709.
35. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. *Endocr Rev* 1994;15:275-300.
36. Peavy DE. Calcium, phosphate, and bone metabolism. In: Rhoades R, Pflanzner R, editors. *Human Physiology*. 2nd ed. Fort Worth: Saunders College Publishing;1992. p 910-935.
37. Watts NB. Clinical utility of biochemical markers of bone remodeling. *Clin Chem* 1999;45:1359-68.
38. Moffet DE, Moffet B, Schauf CL. *Human physiology: foundations and frontiers*. 2nd ed. St Louis: Mosby-Year Book, Inc; 1993. p. 577.
39. Marks SC, Popoff SN. Bone cell biology: the regulation of development, structure, and function in the skeleton. *Am J Anat* 1988;183:1-44.
40. Watkins BA, Lippman HE, Le Bouteiller L, Li Y, Seifert MF. Bioactive fatty acids: role in bone biology and bone cell function. *Progr Lipid Res* 2001;40:125-48.

41. Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. *Endocr Rev* 1993;14:424-42.
42. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. *J Bone Miner Res* 1998;13:793-802.
43. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem Cells* 2001;19:180-92.
44. Maeda S, Nobukuni T, Simo-Onoda K, Hayashi K, Yone K, Komiya S, *et al.* Sortilin is upregulated during osteoblastic differentiation of mesenchymal stem cells and promotes extracellular matrix mineralization. *J Cell Physiol* 2002;193:73-9.
45. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. *J Bone Joint Surg* 2002;84A:1032-44.
46. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* 1997;89:747-54.
47. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, *et al.* Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 1997;89:755-64.
48. Karsenty G. Minireview: Transcriptional control of osteoblast differentiation. *Endocrinology* 2001;142:2731-3.
49. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, De Crombrughe B. The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. *Cell* 2002;108:17-29.
50. Dang ZC, Van Bezooijen RL, Karperien M, Papapoulos SE, Löwik CWGM. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. *J Bone Miner Res* 2002;17:394-405.
51. Dorheim M-A, Sullivan M, Dandapani V, Wu X, Hudson J, Segarini PR, Rosen DM, Aulthouse AL, Gimble JM. Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells. *J Cell Physiol* 1993;154:317-28.
52. Skillington J, Choy L, Derynck R. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes. *J Cell Biol* 2002;159:135-46.

53. Atmani H, Chappard D, Basle MF. Proliferation and differentiation of osteoblasts and adipocytes in rat bone marrow stromal cell cultures: effects of dexamethasone and calcitriol. *J Cell Biochem* 2003;89:364-72.
54. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. *Nature* 2000;405:421-4.
55. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor- γ 2 ligands on adipocyte *versus* osteoblast differentiation. *Endocrinology* 2002;143:2376-84.
56. Diascro DD, Vogel RL, Johnson TE, Witherup KM, Pitzenberger SM, Rutledge SJ, Prescott DJ, Rodan GA, Schmidt A. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. *J Bone Miner Res* 1998;13:96-106.
57. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. *J Bone Miner Res* 1998;13:371-82.
58. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR γ -2 transcription factor and TGF- β /BMP signaling pathways. *Aging Cell* 2004;3:379-89.
59. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, *et al.* Inhibition of *Osf2/Cbfa1* expression and terminal osteoblast differentiation by PPAR γ 2. *J Cell Biochem* 1999;74:357-71.
60. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U, Kubota N, *et al.* PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. *J Clin Invest* 2004;113:846-55.
61. Bellows CG, Heersche JNM. The frequency of common progenitors for adipocytes and osteoblasts and of committed and restricted adipocyte and osteoblast progenitors in fetal rat calvaria cell populations. *J Bone Miner Res* 2001;16:1983-93.
62. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CLH. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. *J Bone Miner Res* 2003;18:599-609.
63. Sugatini T, Alvarez UM, Hruska KA. Activin stimulates I κ B- α /NF κ B and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. *J Cell Biochem* 2003;90:59-67.

64. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. [Review]. *Curr Pharm Des* 2001;7:613-35.
65. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlöndorff J, *et al.* Evidence of a role of a tumor necrosis factor- α (TNF- α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. *J Biol Chem* 1999;274:13613-8.
66. Kong Y-Y, Felge U, Sarosi I, Bolon B, Tafuri A, Morony S, *et al.* Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. *Nature* 1999;402:304-9.
67. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. [Review]. *Osteoporos Int* 2000;11:905-13.
68. Teitelbaum SL. Bone resorption by osteoclasts. [Review]. *Science* 2000;289:1504-8.
69. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, *et al.* Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. *Proc Natl Acad Sci USA* 1990;87:7260-4.
70. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, *et al.* Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *J Biol Chem* 1998;273:14363-7.
71. Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJS, Chandrasekhar S, *et al.* The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. *J Biol Chem* 2000;275:25163-72.
72. Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Burchert A, Schoppet M, *et al.* Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. *J Cell Biochem* 2002;86:642-50.
73. Malyankar UM, Scatena M, Suchland KL, Yun J, Clark EA, Giachelli CM. Osteoprotegerin is an $\alpha_v\beta_3$ -induced, NF- κ B-dependent survival factor for endothelial cells. *J Biol Chem* 2000;275:20959-62.
74. Teng Y-T, Nguyen H, Gao X, Kong Y-Y, Gorczynski RM, Singh B, *et al.* Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. *J Clin Invest* 2000;106:R59-R67.

75. Van Cruchten S, Van den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. *Anat Histol Embryol* 2002;31:214-23.
76. Onishi T, Zhang W, Cao X, Hruska K. The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyclin-dependant kinase 1 (cdc2) in osteoblast precursors. *J Bone Miner Res* 1997;12:1596-605.
77. Huppertz B, Frank HG, Kaufmann P. The apoptosis cascade- morphological and immunohistochemical methods for its visualization. *Anat Embryol* 1999;200:1-18.
78. Kuan N, Passaro E. Apoptosis: Programmed cell death. *Arch Surg* 1998;133:773-5.
79. Hughes DE, Boyce BF. Apoptosis in bone physiology and disease. *Mol Pathol* 1997;50:132-7.
80. Leach A. Apoptosis: molecular mechanism for physiologic cell death. *Clin Lab Sci* 1998;11:346-9.
81. Wang E, Marcotte R, Petroulakis E. Signaling pathway for apoptosis: a racetrack for life or death. *J Cell Biochem (Suppl)* 1999;32/33:95-102.
82. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. *Science* 1995;267:1456-62 .
83. Chung H, Pae H, Choi B, Billiar TR, Kim Y. Nitric oxide as a bioregulator of apoptosis. *Biochem Biophys Res Commun* 2002;282:1075-9.
84. Majno G, Joris I. Apoptosis, oncosis, and necrosis. [Review]. *Am J Pathol* 1995;146:3-15.
85. Bratton DL, Henson PM. Autoimmunity and apoptosis: refusing to go quietly. *Nature Med* 2005;11:26-7.
86. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. *J Cell Sci* 2003;116:4077-85.
87. Lynch MP, Capparelli C, Stein JL, Lian JB. Apoptosis during bone-like tissue development *in vitro*. *J Cell Biochem* 1998;68:31-49.
88. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. *N Eng J Med* 1995;332:305-11.
89. Gowen M. Cytokines and cellular interactions in the control of bone remodelling. In: Heersche JNM, Kanis JA, editors. *Bone and mineral research/8*. Amsterdam Elsevier Science. 1994. p. 77-114.

90. Perez-Amodio S, Beertsen W, Everts V. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts. *J Bone Miner Res* 2004;19:1722-31.
91. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. *J Bone Miner Res* 2003;18:1404-18.
92. Goltzman D. Discoveries, drugs and skeletal disorders. *Nature Rev Drug Discov* 2002;1:784-96.
93. Yaroslavskiy BB, Li Y, Ferguson DJP, Kalla SE, Oakley JI, Blair HC. Autocrine and paracrine nitric oxide regulate attachment of human osteoclasts. *J Cell Biochem* 2004;91:962-72.
94. Raisz LG. Bone cell biology: new approaches and unanswered questions. *Bone Miner Res* 1993;8(Suppl 2):S457-S65.
95. Lerner UH. Modifications of the mouse calvarial technique improve the responsiveness to stimulators of bone resorption. *J Bone Miner Res* 1987;2:375-83.
96. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. *J Bone Miner Res* 1998;13:763-73.
97. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. *Science* 1993;260:626-7.
98. Pacifici R. Estrogen, cytokines, and pathogenesis of post-menopausal osteoporosis [Review]. *J Bone Miner Res* 1996;11:1043-51.
99. Prestwood KM, Thompson DL, Kenny AM, Seibel MJ, Pilbeam CC, Raisz LG. Low dose estrogen and calcium have an additive effect on bone resorption in older women. *J Clin Endocrinol Metab* 1999;84:179-83.
100. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. *J Bone Miner Res* 2002;17:172-8.
101. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. [Review]. *Mol Endocrinol* 1999;13:819-28.

102. Gao Y, Qian W-P, Dark K, Toraldo G, Lin ASP, Guldberg RE, *et al.* Estrogen prevents bone loss through transforming growth factor β signaling in T cells. *Proc Natl Acad Sci USA* 2004;101:16618-23.
103. Saika M, Inoue D, Kido S, Matsumoto T. 17β -estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor- α . *Endocrinology* 2001;142:2205-12.
104. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. *Bone* 2003;32:136-41.
105. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. *Endocrinology* 1999;140:4367-70.
106. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. *Proc Natl Acad Sci USA* 2000;97:7829-34.
107. Riggs BL. The mechanisms of estrogen regulation of bone resorption. *J Clin Invest* 2000;106:1203-4.
108. Rickard DJ, Subramaniam M, Spelsberg TC. Molecular and cellular mechanisms of estrogen action on the skeleton. *J Cell Biochem Suppl* 1999;32/33:123-32.
109. Bell NH. RANK ligand and the regulation of skeletal remodeling. *J Clin Invest* 2003;111:1120-2.
110. Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, *et al.* Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) α or β . *Endocrinology* 2002;143:2349-56.
111. Huang JC, Sakata T, Pflieger LL, Bencsik M, Halloran BP, Bikle DD, *et al.* PTH differentially regulates expression of RANKL and OPG. *J Bone Miner Res* 2004;19:235-44.
112. De Luca HF. Overview of general physiologic features and functions of vitamin D¹⁻⁴. *Am J Clin Nutr* 2004;80(Suppl):1689S-96S.
113. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, *et al.* Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprotegenitor cells in bone marrow. *Bone* 1994;15:717-23.

114. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, *et al.* Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. *J Clin Invest* 1997;99:2961-70.
115. Wang Y-H, Liu Y, Buhl K, Rowe DW. Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. *J Bone Miner Res* 2005;20:5-14.
116. Hock JM, Gera I, Fonseca J, Raisz LG. Human parathyroid hormone-(1-34) increases bone mass in ovariectomised and orchidectomized rats. *Endocrinology* 1988;122:2899-904.
117. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. *J Cell Biochem* 2003;89:180-90.
118. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure. *J Bone Miner Res* 2003;18:1932-41.
119. Spurney RF, Flannery PJ, Garner SC, Athirakul K, Liu S, Guilak F, *et al.* Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. *J Clin Invest* 2002;109:1361-71.
120. Rosen CJ, Bilezikian JP. Anabolic therapy for osteoporosis. [Review]. *J Clin Endocrinol Metab* 2001;86:957-64.
121. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, *et al.* Catabolic effects of continuous human PTH (1-38) *in vivo* is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. *Endocrinology* 2001;142:4047-54.
122. Lee S-K, Lorenzo JA. Regulation of receptor activator of nuclear factor- κ B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase A pathway in murine bone marrow cultures. *Bone* 2002;31:252-9.
123. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, *et al.* *In vivo* demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. *J Bone Miner Res* 2000;15:863-71.
124. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. *Endocrinology* 1998;139:4743-6.

125. Lee S-K, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. *Endocrinology* 1999;140:3552-61.
126. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. *J Clin Invest* 1999;104:439-46.
127. Holick MF. Vitamin D: a millenium perspective. *J Cell Biochem* 2003;88:296-307.
128. Suda T, Ueno Y, Fujii K, Shinki T. Vitamin D and bone. *J Cell Biochem* 2003;88:259-66.
129. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, *et al.* Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. *J Bone Miner Res* 2002;17:622-9.
130. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D₃ supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promotor. *J Cell Biochem* 2003;89:771-7.
131. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocr Rev* 1999;20:345-57.
132. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenic protein-2, and cytokines. *Biochem Biophys Res Commun* 1998;250:776-81.
133. Mundy GR. Cytokines and growth factors in the regulation of bone remodeling. *J Bone Miner Res* 1993;S505-S10.
134. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. *Clin Ortop* 1995;313:36-46.
135. Akatsu T, Takahashi N, Debari K, Morita I, Murota S, Nagata N, *et al.* Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3'5'-monophosphate in mouse bone marrow cell cultures. *J Bone Miner Res* 1989;4:29-35.
136. Collins DA, Chambers TJ. Effect of prostaglandins E₁, E₂, and F_{2α} on osteoclast formation in mouse bone marrow cultures. *J Bone Miner Res* 1991;6:157-64.

137. Kaji H, Sugimoto T, Kanatani M, Fukase M, Kumegawa M, Chihara K. Prostaglandin E₂ stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. *J Bone Miner Res* 1996;11:62-71.
138. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, *et al.* Protein expression and functional difference of membrane-bound and soluble receptor activator of NF- κ B ligand: modulation of the expression by osteotropic factors and cytokines. *Biochem Biophys Res Commun* 2000;275:768-75.
139. Brändström H, Björkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. *Biochem Biophys Res Commun* 2001;280:831-5.
140. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, *et al.* Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. *Proc Natl Acad Sci USA* 1994;91:3228-32.
141. Marshall MJ, Holt I, Davie MW. Inhibition of prostaglandin synthesis leads to a change in adherence of mouse osteoblasts from bone to periosteum. *Calcif Tissue Int* 1996;59:207-13.
142. O'Brien EA, Williams JHH, Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. *Bone* 2001;28:208-14.
143. Jee WSS, Ma YF. The in vivo anabolic actions of prostaglandins in bone. *Bone* 1997;21:297-304.
144. Li M, Jee WSS, Ke HZ, Tang LY, Ma YF, Liang XG, *et al.* Prostaglandin E₂ administration prevents bone loss induced by orchidectomy in rats. *J Bone Miner Res* 1995;10:66-73.
145. Yang R-S, Liu T-K, Lin-Shiau S-Y. Increased bone growth by local prostaglandin E₂ in rats. *Calcif Tissue Int* 1993;52:57-61.
146. Raisz LG, Fall PM. Biphasic effects of prostaglandin E₂ on bone formation in cultured fetal rat calvaria: interaction with cortisol. *Endocrinology* 1990;126:1654-9.
147. McCarthy TL, Centrella M, Raisz LG, Canalis E. Prostaglandin E₂ stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone. *Endocrinology* 1991;128:2895-900.
148. Paralkar VM, Grasser WA, Mansolf AL, Baumann AP, Owen TA, Smock SL, *et al.* Regulation of BMP-7 expression by retinoic acid and prostaglandin E₂. *J Cell Physiol* 2002;190:207-17.

149. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E₂ in human mesenchymal stem cells. *J Cell Physiol* 2004;200:400-6.
150. Kimmel DB, Slovik DM, Lane NE. Current and investigational approaches for reversing established osteoporosis. *Osteoporosis* 1994;20:735-58.
151. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. *J Bone Miner Res* 1993;8(Suppl 2):S565-S72.
152. Karst M, Gorny G, Galvin RJS, Oursler MJ. Roles of stromal cell RANKL, OPG, and M-CFS expression in biphasic TGF- β regulation of osteoclast differentiation. *J Cell Physiol* 2004;200:99-106.
153. Akatsu T, Takahashi N, Udagawa N, Imamura K, Yamaguchi A, Sato K, *et al.* Role of prostaglandins in interleukin-1-induced bone resorption in mice *in vitro*. *J Bone Miner Res* 1991;6:183-90.
154. Marušić A, Raisz LG. Cortisol modulates the actions of interleukin-1 α on bone formation, resorption, and prostaglandin production in cultured mouse parietal bones. *Endocrinology* 1991;129:2699-706.
155. Miyaura C, Inada M, Matsumoto C, Oshiba T, Uozumi N, Shimizu T, *et al.* An essential role of cytosolic phospholipase A₂ α in prostaglandin E₂-mediated bone resorption associated with inflammation. *J Exp Med* 2003;197:1303-10.
156. Gruber R, Nothegger G, Ho G-M, Willheim M, Peterlik M. Differential stimulation of PGE₂ and calcemic hormones of IL-6 in stromal/osteoblastic cells. *Biochem Biophys Res Commun* 2000;270:1080-5.
157. Tai H, Miyaura C, Pilbeam CC, Tamura T, Ohsugi Y, Koishihara Y, *et al.* Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. *Endocrinology* 1997;138:2372-9.
158. Millet I, McCarthy TL, Vignery A. Regulation of interleukin-6 production by prostaglandin E₂ in fetal rat osteoblasts: role of protein kinase A signaling pathway. *J Bone Miner Res* 1998;13:1092-100.
159. Liu X-H, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E₂ signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor- κ β (RANK) ligand/RANK system. *Endocrinology* 2005;146:1991-8.

160. Cunnane SC, Griffin BA. Nutrition and metabolism of lipids. In: Gibney MJ, Vorster HH, Kok FJ, editors. Introduction to human nutrition. 1st ed. Oxford: Blackwell Science; 2002. p. 81-115.
161. Huang Y-S, Nassar BA. Modulation of tissue fatty acid composition, prostaglandin production and cholesterol levels by dietary manipulation of n-3 and n-6 essential fatty acid metabolism. In: Horrobin DF, editor. Omega-6 essential fatty acids. Pathophysiology and roles in clinical medicine. New York: Wiley-Liss; 1990. p. 127-144.
162. Horrobin DF, Manku MS. Clinical biochemistry of essential fatty acids. In: Horrobin DF, editor. Omega-6 essential fatty acids. Pathophysiology and roles in clinical medicine. New York: Wiley-Liss; 1990. p. 21-53.
163. Haag M. Poly-unsaturated fatty acids: their cellular role and clinical applications (Part 1). [Review]. The Medicine J (SA) 2001;43:13-7.
164. Clandinin MT, Van Aerde JE, Parrott A, Field CJ, Euler CJ, Lien EL. Assessment of the efficacious dose of arachidonic acid and docosahexaenoic acids in preterm infant formulas: fatty acid composition of erythrocyte membrane lipids. *Pediatr Res* 1997;42:819-25.
165. Kruger MC, Claassen N, Smuts CM, Potgieter HC. Correlation between essential fatty acids and parameters of bone formation and degradation. *Asia Pacific J Clin Nutr* 1997;6:235-8.
166. Williams EE, May BD, Stillwell W, Janski LJ. Docosahexaenoic acid (DHA) alters the phospholipid molecular species composition of membranous vesicles exfoliated from the surface of a murine leukemia cell line. *Biochim Biophys Acta* 1999;1418:185-96.
167. Otto SJ, v Houwelingen AC, Hornstra G. The effect of different supplements containing docosahexaenoic acid on plasma and erythrocyte fatty acids of healthy non-pregnant women. *Nutr Res* 2000;20:917-27.
168. Coetzer H, Claassen N, van Papendorp DH, Kruger MC. Calcium transport by isolated brush border and basolateral membrane vesicles: role of essential fatty acid supplementation. *Prostaglandins Leukot Essent Fatty Acids* 1994;50:257-66.
169. Haag M, Magada ON, Claassen N, Böhmer LH, Kruger MC. Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:423-29.
170. Smith WL. Prostanoid biosynthesis and mechanism of action. *Am J Physiol* 1992;263:F181-F91.

171. Corwin RL. Effects of dietary fats on bone health in advanced age. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:379-86.
172. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. *Proc Natl Acad Sci USA* 1983;80:3581-4.
173. Watkins BA, Shen C-L, McMurtry JP, Xu H, Bain SD, Allen KGD, *et al.* Dietary lipids modulate bone prostaglandin E₂ production, insulin-like growth factor-1 concentration and formation rate in chicks. *J Nutr* 1997;127:1084-91.
174. Li Y, Seifert MF, Ney DM, Grahn M, Grant AL, Allen KGD, *et al.* Dietary conjugated linoleic acids alter serum IGF-I and IGF binding protein concentrations and reduce bone formation in rats fed (n-6) or (n-3) fatty acids. *J Bone Miner Res* 1999;14:1153-62.
175. Lucia VD, Fitzpatrick-Wong SC, Weiler HA. Dietary arachidonic acid suppresses bone turnover in contrast to low dosage exogenous prostaglandin E₂ that elevates bone formation in the piglet. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:407-13.
176. Watkins BA, Li Y, Lippman HE, Seifert MF. Omega-3 polyunsaturated fatty acids and skeletal health. [Review]. *Exp Biol Med* 2001;226:485-97.
177. Raisz LG, Alander CB, Simmons HA. Effects of prostaglandin E₃ and eicosapentaenoic acid on rat bone in organ culture. *Prostaglandins* 1989;37:615-25.
178. Laneuville O, Breuer DK, Xu N, Huang ZH, Gage DA, Watson JT, *et al.* Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. *J Biol Chem* 1995;270:19330-6.
179. Khan WA, Blobe GC, Hannun YA. Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C. [Review]. *Cell Signal* 1995;7:171-84.
180. Speizer LA, Watson MJ, Brunton LL. Differential effects of omega-3 fish oils on protein kinase activities *in vitro*. *Am J Physiol* 1991;261:E109-E14.
181. Mirnikjoo B, Brown SE, Kim HFS, Marangell LB, Sweatt JD, Weeber EJ. Protein kinase inhibition by ω -3 fatty acids. *J Biol Chem* 2001;276:10888-96.
182. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. [Review]. *J Biol Chem* 2002;277:8755-8.
183. Duplus E, Glorian M, Forest C. Fatty acid regulation of gene transcription. [Review]. *J Biol Chem* 2000;275:30749-52.

184. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, *et al.* Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ . *Proc Natl Acad Sci USA* 1997;94:4318-23.
185. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, *et al.* Interleukin-4-dependent production of PPAR- γ ligands in macrophages by 12/15-lipoxygenase. *Nature* 1999;400:378-82.
186. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. [Review]. *Endocr Rev* 1999;20:649-88.
187. Wolf G. Fatty acids bind directly to and activate peroxisome proliferator-activated receptors α and γ . *Nutr Rev* 1998;56:61-3.
188. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ . *Proc Natl Acad Sci USA* 1997;94:4312-7.
189. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. *Cell* 1994;79:1147-56.
190. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR γ . *Cell* 1995;83:803-12.
191. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J₂ metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. *Cell* 1995;83:813-9.
192. Nunez EA. Free fatty acids as modulators of the steroid hormone message. *Prostaglandins Leukot Essent Fatty Acids* 1993;48:63-70.
193. Stepankova R, Funda DP, Smetana K. Essential fatty acid deficiency and bone fragility in rats. *Folia Biologica* 1996;42:257-9.
194. Borland VG, Jackson CM. Effects of a fat-free diet on the structure of the kidney in rats. *Arch Pathol* 1931;11:687-708.
195. Marum GJ. Roentgenographic observations in age atrophy and osteoporosis of the spine. *Radiology* 1946;46:220-6.
196. Demer LL. A skeleton in the atherosclerosis closet. *Circulation* 1995;92:2029-32.

197. Buck AC, Davies RL, Harrison T. The protective role of eicosapentaenoic acid [EPA] In the pathogenesis of nephrolithiasis. *J Urol* 1991;146:188-94.
198. Burgess NA, Reynolds TM, Williams N, Pathy A, Smith S. Evaluation of four models of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acids on calcification. *Urol Res* 1995;23:239-42.
199. Sakaguchi K, Morita I, Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. *Prostaglandin Leukot Essent Fatty Acids* 1994;50:81-4.
200. Yamada Y, Fushimi H, Inoue T, Matsuyama Y, Kameyama M, Minami T, *et al.* Effect of eicosapentaenoic acid and docosahexanoic acid on diabetic osteopenia. *Diabetes Res Clin Pract* 1995;30:37-42.
201. Green KH, Fitzpatrick Wong SCF, Weiler HA. The effect of dietary n-3 long chain polyunsaturated fatty acids on femur mineral density and biomarkers of bone metabolism in healthy, diabetic and dietary-restricted growing rats. *Prostaglandins Leukot Essent Fatty Acids* 2004;71:121-130.
202. Reinwald S, Li Y, Moriguchi T, Salem N, Watkins BA. Repletion with (n-3) fatty acids reverses bone structural deficits in (n-3)-deficient rats. *J Nutr* 2004;134:388-94.
203. Blararu JL, Kohut JR, Fitzpatrick-Wong SC, Weiler HA. Dose response of bone mass to dietary arachidonic acid in piglets fed cow milk-based formula. *Am J Clin Nutr* 2004;79:139-47.
204. Norrdin RW, Jee WSS, High WB. The role of prostaglandins in bone. [Review]. *Prostaglandins Leukot Essent Fatty acids* 1990;41:139-49.
205. Watkins BA, Li Y, Allen KGD, Hoffman WE, Seifert MF. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. *J Nutr* 2000;130:2274-84.
206. Claassen N, Potgieter HC, Seppa M, Vermaak WJH, Coetzer H, van Papendorp DH, *et al.* Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks, total urinary hydroxyproline, and bone calcium content. *Bone* 1995;16:385S-92S.
207. Watkins BA, Shen C-L, Allen KGD, Seifert MF. Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter ex vivo PGE₂ biosynthesis, tissue IGF-I levels, and bone morphometry in chicks. *J Bone Miner Res* 1996;11:1321-32.

208. Sasaki T, Kanke Y, Kudoh K, Misawa Y, Shimizu J, Takita T. Effects of dietary docosahexaenoic acid on surface molecules involved in T cell proliferation. *Biochim Biophys Acta* 1999;1436:519-30.
209. James MJ, Proudman SM, Cleland LG. Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:399-405.
210. Judex S, Wohl GR, Wolff RB, Leng W, Gillis AM, Zernicke RF. Dietary fish oil supplementation adversely affects cortical bone morphology and biomechanics in growing rabbits. *Calcif Tissue Int* 2000;66:443-8.
211. Sirois I, Cheung AM, Ward WE. Biomechanical bone strength and bone mass in young male and female rats are fed a fish oil diet. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:415-21.
212. Weiler HA, Fitzpatrick-Wong SC. Modulation of essential (n-6):(n-3) fatty acids ratio alters fatty acid status but not bone mass in piglets. *J Nutr* 2002;132:2667-72.
213. Weiler HA. Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs. *Pediatr Res* 2000;47:692-7.
214. Weiler HA, Fitzpatrick-Wong SC. Dietary long-chain polyunsaturated fatty acids minimize dexamethasone-induced reductions in arachidonic acid status but not bone mineral content in piglets. *Pediatr Res* 2002;51:282-9.
215. Burke A, Weiler H. The effect of prostaglandin E₂ (PGE₂) and long-chain polyunsaturated fatty acids (LC PUFA) on bone formation in piglets: a model for bone growth in nutritional investigation. *Prostaglandin Leukot Essent Fatty Acids* 2002;67:229-35.
216. Liu D, Denbow DM. Maternal dietary lipids modify composition of bone lipids and ex vivo prostaglandin E₂ production in early postnatal Japanese quail. *Poultry Sci* 2001;80:1344-52.
217. DiBattista JA, Dore S, Morin N, Aribat T. Prostaglandin E₂ up-regulates insulin-like growth factor binding protein-3 expression and synthesis in human articular chondrocytes by a c-AMP-independent pathway: role of calcium and protein kinase A and C. *J Cell Biochem* 1996;63:320-33.
218. Watkins BA, Seifert MF. Conjugated linoleic acid and bone biology. *J Am Coll Nutr* 2000;19:478S-86S.

219. Schmid C, Schläpfer I, Waldvogel M, Zapf J, Froesch ER. Prostaglandin E₂ stimulates synthesis of insulin-like growth factor binding protein-3 in rat bone cells *in vitro*. *J Bone Miner Res* 1992;7:1157-63.
220. Delany AM, Pash JM, Canalis E. Cellular and clinical perspectives on skeletal insulin-like growth factor I. [Review] *J Cell Biochem* 1994;55:328-33.
221. McCarthy TL, Casinghino S, Centrella M, Canalis E. Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E₂, growth hormone, and the insulin-like growth factors. *J Cell Physiol* 1994;160:163-75.
222. Hakeda Y, Kawaguchi H, Hand A, Pilbeam C, Hurley M, Abreu C, *et al*. Insulin-like growth factor binding protein-5 accumulates in bone matrix and is released by parathyroid hormone and prostaglandin E₂. *J Bone Miner Res* 1993;8:S237.
223. Watkins BA, Li Y, Lippman HE, Feng S. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. *Prostaglandins Leukot Essent Fatty Acids* 2003;68:387-98.
224. Zhang X, Schwartz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. *J Clin Invest* 2002;109:1405-15.
225. Liu C, Chang E, Yu J, Carlson CS, Prazak L, Yu X-P, *et al*. The interferon-inducible p204 protein acts as a transcriptional coactivator of Cbfa1 and enhances osteoblast differentiation. *J Biol Chem* 2005;280:2788-96.
226. Priante G, Bordin L, Musacchio E, Clari G, Baggio B. Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid. *Clin Sci* 2002;102:403-9.
227. Zeitlin L, Segev E, Fried A, Wientroub S. Effects of long-term administration of n-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice. *J Cell Biochem* 2003;90:347-60.
228. Harrison JR, Lorenzo JA, Kawaguchi H, Raisz LG, Pilbeam C. Stimulation of prostaglandin E₂ production by interleukin-1 α and transforming growth factor α in osteoblastic MC3T3-E1 cells. *J Bone Miner Res* 1994;9:817-23.
229. Suda M, Tanaka K, Natsui K, Usui T, Tanaka I, Fukushima M, *et al*. Prostaglandin E receptor subtypes in mouse osteoblastic cell line. *Endocrinology* 1996;137:1698-1705.

230. Vane JR, Botting RM. Overview-mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs. COX-2 enzyme inhibitors. Proceedings of a conference; 1995 Oct 10-11; London, England. Dordrecht: Kluwer Academic Publishers and William Harvey Press, 1996:1-27.
231. Kanematsu M, Ikeda K, Yamada Y. Interaction between nitric oxide synthase and cyclooxygenase pathways in osteoblastic MC3T3-E1 cells. *J Bone Miner Res* 1997;12: 1789-96.
232. Suda M, Tanaka K, Yasoda A, Natsui K, Sakuma Y, Tanaka I, *et al.* Prostaglandin E₂ (PGE₂) autoamplifies its production through EP₁ subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells. *Calcif Tissue Int* 1998;62:327-31.
233. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, *et al.* Regulation of prostaglandin E₂ biosynthesis by inducible membrane-associated prostaglandin E₂ synthase that acts in concert with cyclooxygenase-2. *J Biol Chem* 2000;275:32783-92.
234. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, *et al.* Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. *J Biol Chem* 1995;270: 10902-8.
235. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology. Classification of prostanoid receptors: properties, distribution, and structures of the receptors and their subtypes. *Pharmacol Rev* 1994;46:205-29.
236. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. *J Clin Invest* 2001;108:25-30.
237. Raisz LG, Simmons HA. Effects of parathyroid hormone and cortisol on prostaglandin production by neonatal rat calvaria *in vitro*. *Endocr Res* 1985;11:59-74.
238. Raisz LG. The role of prostaglandins in the local regulation of bone metabolism. In: Molecular and cellular regulation of calcium and phosphate metabolism. Alan R Liss, Inc, 1990. p 195-203.
239. Shinar DM, Rodan GA. Biphasic effects of transforming growth factor- β on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells. *Endocrinology* 1990;126:3153-8.
240. Okada Y, Pilbeam C, Raisz LG, Tanaka Y. Role of cyclooxygenase-2 in bone resorption. *J UOEH* 2003;25:185-95.

241. Schwartz Z, Dennis R, Bonewald L, Swain J, Gomez R, Boyan BD. Differential regulation of prostaglandin E₂ synthesis and phospholipase A₂ activity by 1,25-(OH)₂D₃ in three osteoblast-like cell lines (MC3T3-E1, ROS 17/2.8, and MG-63) cells. *Bone* 1992;13:51-8.
242. Klein-Nulend J, Pilbeam CC, Raisz LG. Effect of 1,25-dihydroxyvitamin D₃ on prostaglandin E₂ production in cultured mouse parietal bones. *J Bone Miner Res* 1991;6:1339-44.
243. Pilbeam CC, Kawaguchi H, Hakeda Y, Voznesensky O, Alander CB, Raisz LG. Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells. *J Biol Chem* 1993;268:25643-9.
244. Takahashi Y, Taketani Y, Endo T, Yamamoto S, Kumegawa M. Studies on the induction of cyclooxygenase isozymes by various prostaglandins in mouse osteoblastic cell line with reference to signal transduction pathways. *Biochim Biophys Acta* 1994; 1212:217-24.
245. Pilbeam CC, Raisz LG, Voznesensky O, Alander CB, Delman BN, Kawaguchi H. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. *J Bone Miner Res* 1995;10:406-14.
246. Sakuma Y, Li Z, Pilbeam CC, Alander CB, Chikazu D, Kawaguchi H, *et al.* Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E₂ and selective prostaglandin receptor agonists in murine osteoblastic cells. *Bone* 2004;34:827-34.
247. Tanabe N, Maeno M, Suzuki N, Fujisaki K, Tanaka B, Ogiso B, *et al.* IL-1 α stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE₂ production and decreasing OPG production by osteoblasts. *Life Sci* 2005;77:615-26.
248. Min Y-K, Rao Y, Okada Y, Raisz LG, Pilbeam CC. Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. *J Bone Miner Res* 1998;13:1066-75.
249. Lauderkind SJF, Kirtikara K, Raghov R, Ballou LR. The regulation of PGE₂ biosynthesis in MG-63 osteosarcoma cells by IL-1 and FGF is cell density- dependent. *Exp Cell Res* 2000;258:409-16.
250. Hurley MM, Fall P, Harrison JR, Petersen DN, Kream BE, Raisz LG. Effects of transforming growth factor α and interleukin-1 on DNA synthesis, collagen synthesis, procollagen mRNA levels, and prostaglandin E₂ production. *J Bone Miner Res* 1989;4:731-6.
251. Lerner UH. Transforming growth factor- β stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway. *J Bone Miner Res* 1996;11:1628-39.

252. Pilbeam CC, Fall PM, Alander CB, Raisz LG. Differential effects of nonsteroidal anti-inflammatory drugs on constitutive and inducible prostaglandin G/H synthase in cultured bone cells. *J Bone Miner Res* 1997;12:1198-203.
253. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity *in vitro*. *Prostaglandins* 1994;47:55-9.
254. Glew RH. Lipid metabolism II: Pathways of metabolism of special lipids. In: Devlin TM, editor. *Textbook of Biochemistry*. 3rd ed. New York: Wiley-Liss;1992. p424-471.
255. Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits EA. Antiemetic efficacy of dexamethasone. *N Engl J Med* 1984;311:549-52.
256. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong W, *et al*. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. *J Biol Chem* 1992;267:25934.
257. Gardner CR, Blaque R, Cottereaux C. Mechanisms involved in prostaglandin-induced increase in bone resorption in neonatal mouse calvaria. *Prostaglandins Leukot Essent Fatty Acids* 2001;64:117-25.
258. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, *et al*. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. *Proc Natl Acad Sci USA* 2002;99:4580-5.
259. Akhter MP, Cullen DM, Gong G, Recker RR. Bone biomechanical properties in prostaglandin EP₁ and EP₂ knockout mice. *Bone* 2001;29:121-5.
260. Miyamoto K-I, Suzuki H, Yamamoto S, Saitoh Y, Ochiai E, Moritani S, *et al*. Prostaglandin E₂-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the *in vitro* bone marrow culture. *J Bone Miner Res* 2003;18:1471-7.
261. Centrella M, Casinghino S, McCarthy TL. Differential actions of prostaglandins in separate cell populations from fetal rat bone. *Endocrinology* 1994;135:1611-20.
262. Woodiel FN, Fall PM, Raisz LG. Anabolic effects of prostaglandins in cultured fetal rat calvariae: structure-activity relations and signal transduction pathway. *J Bone Miner Res* 1996;11:1249-55.
263. Yamaguchi DT, Green J, Merritt BS, Kleeman CR, Muallem S. Modulation of osteoblast function by prostaglandins. *Am J Physiol* 1989;257:F755-F61.

264. Fang MA, Kujubu DA, Hahn TJ. The effects of prostaglandin E₂, parathyroid hormone, and epidermal growth factor on mitogenesis, signaling, and primary response genes in UMR 106-01 osteoblast-like cells. *Endocrinology* 1992;131:2113-9.
265. Ho M, Chang J-K, Chuang L, Hsu H, Wang G. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. *Biochem Pharmacol* 1999;58:983-90.
266. Fujimori A, Tsutsumi M, Fukase M, Fujita T. Cyclooxygenase inhibitors enhance cell growth in an osteoblastic cell line, MC3T3-E1. *J Bone Miner Res* 1989;4:697-704.
267. Baylink TM, Mohan S, Fitzsimmons RJ, Baylink DJ. Evaluation of signal transduction mechanisms for the mitogenic effects of prostaglandin E₂ in normal human bone cells *in vitro*. *J Bone Miner Res* 1996;11:1413-8.
268. Gronowicz GA, Fall PM, Raisz LG. Prostaglandin E₂ stimulates preosteoblast replication: an autoradiographic study in cultured fetal rat calvariae. *Exp Cell Res* 1994;212:314-20.
269. Scutt A, Bertram P. Bone marrow cells are targets for the anabolic actions of prostaglandin E₂ on bone: induction of a transition from nonadherent to adherent osteoblast precursors. *J Bone Miner Res* 1995;10:474-87.
270. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Role of endogenous PGE₂ in osteoblastic functions of a clonal osteoblast-like cell, MC3T3-E1. *Prostaglandins Leukot Essent Fatty Acids* 1994;50:169-72.
271. Kajii T, Suzuki K, Yoshikawa M, Imai T, Matsumoto A, Nakamura S. Long-term effects of prostaglandin E₂ on the mineralization of a clonal osteoblastic cell line (MC3T3-E1). *Arch Oral Biol* 1999;44:233-41.
272. Fall PM, Breault DT, Raisz LG. Inhibition of collagen synthesis by prostaglandins in the immortalized rat osteoblastic cell line Py1a: structure-activity relations and signal transduction mechanisms. *J Bone Miner Res* 1994;9:1935-43.
273. Flanagan AM, Chambers TJ. Stimulation of bone nodule formation *in vitro* by prostaglandins E₁ and E₂. *Endocrinology* 1992;130:443-8.
274. Tang LY, Kimmel DB, Jee WSS, Yee JA. Functional characterization of prostaglandin E₂ inducible osteogenic colony forming units in cultures of cells isolated from the neonatal rat calvarium. *J Cell Physiol* 1996;166:76-83.
275. Kaneki H, Takasugi I, Fujieda M, Kiri M, Mizuochi S, Ide H. Prostaglandin E₂ stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. *J Cell Biochem* 1999;73:36-48.

276. Krieger NS, Parker WR, Alexander KM, Bushinsky DA. Prostaglandins regulate acid-induced cell-mediated bone resorption. *Am J Physiol Renal Physiol* 2000;279:F1077-F82.
277. Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, *et al.* Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. *J Clin Invest* 2000;105:823-32.
278. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CRJ, Breyer RM, *et al.* Knockout of the murine prostaglandin EP₂ receptor impairs osteoclastogenesis *in vitro*. *Endocrinology* 2000;141:2054-61.
279. Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, *et al.* Impaired bone resorption to prostaglandin E₂ in prostaglandin E receptor EP4-knockout mice. *J Biol Chem* 2000;275:19819-23.
280. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, *et al.* The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. *Endocrinology* 2000;141:1554-9.
281. Tomita M, Li X, Okada Y, Woodiel FN, Young RN, Pilbeam CC, *et al.* Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption *in vitro*. *Bone* 2002;30:159-63.
282. Wani MR, Fuller K, Kim NS, Choi Y, Chambers T. Prostaglandin E₂ cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. *Endocrinology* 1999;140:1927-35.
283. Kobayashi Y, Mizoguchi T, Take I, Kurihara S, Udagawa N, Takahashi N. Prostaglandin E₂ enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. *J Biol Chem* 2005;280:11395-403.
284. Okamoto F, Kajiya H, Fukushima H, Jimi E, Okabe K. Prostaglandin E₂ activates outwardly rectifying Cl⁻ channels via a c-AMP-dependent pathway and reduces cell motility in rat osteoclasts. *Am J Physiol Cell Physiol* 2004;287:C114-C24.
285. Sudo H, Kodama H-A, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. *J Cell Biol* 1983;96:191-8.
286. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. *Proc Natl Acad Sci USA* 1986;83:2496-500.

287. Moreno-Cuevas JE, Sirbasku DA. Estrogen mitogenic action. III. Is phenol red a "red herring"? *In Vitro Cell Dev Biol Anim* 2000;36:447-64.
288. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. *Endocrinology* 1978;103:1742-51.
289. Harada S-I, Matsumoto T, Ogata E. Role of ascorbic acid in the regulation of proliferation in osteoblast-like MC3T3-E1 cells. *J Bone Miner Res* 1991;6:903-8.
290. Lennon DP, Haynesworth SE, Young RG, Dennis JE, Caplan AI. A chemically defined medium supports *in vitro* proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells. *Exp Cell Res* 1995;219:211-22.
291. Shui C, Scutt AM. Mouse embryo-derived NIH3T3 fibroblasts adopt an osteoblast-like phenotype when treated with $1\alpha,25$ -dihydroxyvitamin D₃ and dexamethasone *in vitro*. *J Cell Physiol* 2002;193:164-72.
292. Bodine PVN, Trailsmith M, Komm BS. Development and characterization of a conditionally transformed adult human osteoblastic cell line. *J Bone Miner Res* 1996;11:806-19.
293. Rosa AL, Beloti MM. TAK-778 enhances osteoblast differentiation of human bone marrow cells. *J Cell Biochem* 2003;89:1148-53.
294. Herbertson A, Aubin JE. Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures. *J Bone Miner Res* 1995;10:285-94.
295. Aubin JE. Osteoprogenitor cell frequency in rat bone marrow stromal populations: role of heterotypic cell-cell interactions in osteoblast differentiation. *J Cell Biochem* 1999;72:396-410.
296. Porter RM, Huckle WR, Goldstein AS. Effect of dexamethasone withdrawal on osteoblastic differentiation of bone marrow stromal cells. *J Cell Biochem* 2003;90:13-22.
297. Freshney RI. *Culture of animal cells: a manual of basic technique*. 4th ed. New York: Wiley-Liss; 2000. p.184.
298. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. *Anal Biochem* 1986;159:109-13.
299. Shui C, Scutt AM. Mild heat shock induces proliferation, alkaline phosphatase activity, and mineralization in human bone marrow stromal cells and Mg-63 cells *in vitro*. *J Bone Miner Res* 2001;16:731-41.

300. Joubert AM, Panzer A, Joubert F, Lottering M-L, Bianchi PC, Seegers JC. Comparative study of the effects of polyunsaturated fatty acids and their metabolites on cell growth and tyrosine kinase activity in oesophageal carcinoma cells. *Prostaglandins Leukot Essent Fatty Acids* 1999;61:171-82.
301. De Kock M, Lottering M-L, Seegers JC. Differential cytotoxic effects of gamma-linolenic acid on MG-63 and HeLa cells. *Prostaglandins Leukot Essent Fatty Acids* 1994;51:109-20.
302. Kiernan J. *Histological and histochemical methods*. 2nd Edition. London: Pergamon Press, 1990. p. 96-97.
303. Ciancio G, Pollack A, Taupier MA, Block NL, Irvin III GL. Measurement of cell-cycle phase-specific cell death using Hoechst 33342 and propidium iodide: preservation by ethanol fixation. *J Histochem Cytochem* 1988;36:1147-52.
304. Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, *et al.* Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. *J Cell Physiol* 1990;143:420-30.
305. Feuerbach D, Loetscher E, Buerki K, Sampath TK, Feyen JHM. Establishment and characterization of conditionally immortalized stromal cell lines from a temperature-sensitive T-Ag transgenic mouse. *J Bone Miner Res* 1997;12:179-90.
306. Yang X, Tare RS, Partridge KA, Roach HI, Clarke NMP, Howdle SM, *et al.* Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotropin: osteoconductive biomimetic scaffolds for tissue engineering. *J Bone Miner Res* 2003;18:47-57.
307. Ramírez-Zacarias JL, Castro-Muñozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. *Histochemistry* 1992;97:493-7.
308. Osteoprotegerin. Enzyme immunoassay for the quantitative determination of osteoprotegerin in EDTA plasma, heparin plasma, serum or cell culture supernatants. ELISA kit protocol. Cat. No. BI-20402. Biomedica Medizinprodukte GmbH&Co KG, Vienna.
309. Liu Z-J, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. *J Steroid Biochem Mol Biol* 2004;88:265-75.
310. Mueck AO, Seeger H, Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol? *Life Sci* 2004;75:1205-10.

311. Chow JWM, Lean JM, Abe T, Chambers TJ. The anabolic effect of 17β -oestradiol on the trabecular bone of adult rats is suppressed by indomethacin. *J Endocrinol* 1992;133:189-95.
312. Samuels A, Perry MJ, Tobias JH. High-dose estrogen-induced osteogenesis in the mouse is partially suppressed by indomethacin. *Bone* 1999;25:675-80.
313. Maciel FMB, Sarrazin P, Morisset S, Lora M, Patry C, Dumais R, *et al.* Induction of cyclooxygenase-2 by parathyroid hormone in human osteoblasts in culture. *J Rheumatol* 1997;24:2429-35.
314. Kawaguchi H, Raisz LG, Voznesensky OS, Alander CB, Hakeda Y, Pilbeam CC. Regulation of the two prostaglandin G/H synthases by parathyroid hormone, interleukin-1, cortisol, and prostaglandin E_2 in cultured neonatal mouse calvariae. *Endocrinology* 1994;135:1157-64.
315. Klein-Nulend J, Pilbeam CC, Harrison JR, Fall PM, Raisz LG. Mechanism of regulation of prostaglandin production by parathyroid hormone, interleukin-1, and cortisol in cultured mouse parietal bones. *Endocrinology* 1991;128:2503-10.
316. Jakobsson P-H, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proc Natl Acad Sci USA* 1999;96:7220-5.
317. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E_2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E_2 biosynthesis. *J Biol Chem* 2000;275:32775-82.
318. Saegusa M, Murakami M, Nakatani Y, Yamakawa K, Katagiri M, Matsuda K, *et al.* Contribution of membrane-associated prostaglandin E_2 synthase to bone resorption. *J Cell Physiol* 2003;197:348-56.
319. Hamilton LC, Mitchell JA, Tomlinson AM, Warner TD. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply *in vivo*: consequences for nonsteroidal antiinflammatory drug efficacy. *FASEB J* 1999;13:245-51.
320. Chen X, Garner SC, Quarles LD, Anderson JJB. Effects of Genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. *J Nutr Biochem* 2003;14:342-9.
321. MacDonald BR, Gallagher JA, Ahnfelt-Ronne I, Beresford JN, Gowen M, Russel GG. Effects of bovine parathyroid hormone and 1,25-dihydroxyvitamin D_3 on the production of prostaglandins by cells derived from human bone. *FEBS letters* 1984;169:49-52.

322. Klein-Nulend J, Bowers PN, Raisz LG. Evidence that adenosine 3'5'-monophosphate mediates hormonal stimulation of prostaglandin production in cultured mouse parietal bones. *Endocrinology* 1990;126:1070-5.
323. Van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. *Annu Rev Cell Biol* 1994;10:251-337.
324. Verheijen MHG, Defize LHK. Parathyroid hormone inhibits mitogen-activated protein kinase activation in osteosarcoma cells via a protein kinase A-dependent pathway. *Endocrinology* 1995;136:3331-7.
325. Cotter TG, Lennon SV, Glynn JM, Green DR. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis. *Cancer Res* 1992;52:997-1005.
326. Seegers JC, de Kock M, Lottering M-L, Grobler CJS, van Papendorp DH, Shou Y, *et al.* Effects of gamma-linolenic acid and arachidonic acid on cell cycle progression and apoptosis induction in normal and transformed cells. *Prostaglandins Leukot Essent Fatty Acids* 1997;56:271-80.
327. Tessier C, Fayard J-M, Cohen H, Pageaux J-F, Lagarde M, Laugier C. Docosahexaenoic acid is a potent inhibitor of rat uterine stromal cell proliferation. *Biochem Biophys Res Commun* 1995;207:1015-21.
328. Shiina T, Terano T, Saito J, Tamura Y, Yoshida S. Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells. *Atherosclerosis* 1993;104:95-103.
329. Albino AP, Juan G, Traganos F, Reinhart L, Connolly J, Rose DP, *et al.* Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: Association with decreased pRb phosphorylation. *Cancer Res* 2000;60:4139-45.
330. Maurin AC, Chavassieux PM, Vericel E, Meunier PJ. Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. *Bone* 2002;31:260-6.
331. Rose DP, Connolly JM. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. *Cancer Res* 1990;50:7139-44.
332. Danesch U, Weber PC, Sellmayer A. Differential effects of n-6 and n-3 polyunsaturated fatty acids on cell growth and early gene expression in Swiss 3T3 fibroblasts. *J Cell Physiol* 1996;168:618-24.

333. Siddiqui RA, Jenski LJ, Neff K, Harvey K, Kovacs RJ, Stillwell W. Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. *Biochim Biophys Acta* 2001; 1499:265-75.
334. Hori T, Yamanaka Y, Hayakawa M, Shibamoto S, Oku N, Ito F. Growth inhibition of human fibroblasts by epidermal growth factor in the presence of arachidonic acid. *Biochem Biophys Res Commun* 1990;169:959-65.
335. Terano T, Tanaka T, Tamura Y, Kitagawa M, Higashi H, Saito Y, *et al.* Eicosapentaenoic acid and docosahexaenoic acid inhibit vascular smooth muscle cell proliferation by inhibiting phosphorylation of Cdk2-cyclinE complex. *Biochem Biophys Res Commun* 1999;254:502-6.
336. Stillwell W, Ehringer W, Jenski LJ. Docosahexaenoic acid increases permeability of lipid vesicles and tumor cells. *Lipids* 1993;28:103-8.
337. Abdel-Malek ZA, Swope VB, Trinkle LS, Ferroni EN, Boissy RE, Nordlund JJ. Alteration of the Cloudman melanoma cell cycle by prostaglandins E₁ and E₂ determined by using a 5-bromo-2'-deoxyuridine method of DNA analysis. *J Cell Physiol* 1988;136:247-56.
338. Fujieda M, Kiri M, Mizuochi S, Hagiya K, Kaneki H, Ide H. Formation of mineralized bone nodules by rat calvarial osteoblasts decreases with donor age due to a reduction in signaling through EP₁ subtype of prostaglandin E₂ receptor. *J Cell Biochem* 1999;75:215-25.
339. Dommels YEM, Haring MMG, Kestra NGM, Alink GM, van Bladeren PJ, van Ommen B. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE₂ synthesis and cytotoxicity in human colorectal carcinoma cell lines. *Carcinogenesis* 2003;24:385-92.
340. Das UN. Essential fatty acids, lipid peroxidation and apoptosis. *Prostaglandins Leukot Essent Fatty Acids* 1999;61:157-63.
341. Pompeia C, Lima T, Curi R. Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death? *Cell Biochem Funct* 2003;21:97-104.
342. Umegaki K, Hashimoto M, Yamasaki H, Fujii Y, Yoshimura M, Sugisawa A, *et al.* Docosahexaenoic acid supplementation-increased oxidative damage in bone marrow DNA in aged rats and its relation to antioxidant vitamins. *Free Rad Res* 2001;34:427-35.
343. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, *et al.* Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J Biol Chem* 1995;270:23975-83.

344. Cheng MZ, Rawlinson SCF, Pitsillides AA, Zaman G, Mohan S, Baylink DJ, *et al.* Human osteoblasts' proliferative responses to strain and 17 β -estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I. *J Bone Miner Res* 2002;17:593-602.
345. Lieberherr M, Grosse B, Kachkache M, Balsan S. Cell signaling and estrogens in female rat osteoblasts: a possible involvement of unconventional nonnuclear receptors. *J Bone Miner Res* 1993;8:1365-1376
346. Lorenzo J. A new hypothesis for how sex steroid hormones regulate bone mass. *J Clin Invest* 2003;111:1641-1653
347. Fohr B, Schultz A, Battmann A. Sex steroids and bone metabolism: Comparison of *in vitro* effects of 17 β -estradiol and testosterone on human osteosarcoma cell lines of various gender and differentiation. *Exp Clin Endocrinol Diabetes* 2000;108:414-23.
348. MacDonald BR, Gallagher JA, Russell RGG. Parathyroid hormone stimulates the proliferation of cells derived from human bone. *Endocrinology* 1986;118:2445-9.
349. Qin L, Li X, Ko J-K, Partridge NC. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G₁ to S phase. *J Biol Chem* 2005;280:3104-111.
350. Ramesh G, Das UN, Koratkar R, Padma M, Sagar PS. Effect of essential fatty acids on tumor cells. *Nutrition* 1992;8:343-7.
351. Williams JR, Leaver HA, Ironside JW, Miller EP, Whittle IR, Gregor A. Apoptosis in human primary brain tumours: actions of arachidonic acid. *Prostaglandins Leukot Essent Fatty Acids* 1998;58:193-200.
352. Brown DM, Warner GL, Alés-Martínez JE, Scott DW, Phipps RP. Prostaglandin E₂ induces apoptosis in immature normal and malignant B lymphocytes. *Clin Immunol Immunopathol* 1992;63:221-9.
353. Stanford CM, Jacobson PA, Eanes ED, Lembke LA, Midura RJ. Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). *J Biol Chem* 1995;270:9420-8.
354. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an *in vitro* model of osteoclast development. *J Bone Miner Res* 1992;7:683-92.

355. Aronow MA, Gerstenfeld LC, Owen TA, Tassinari MS, Stein GS, Lian JB. Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. *J Cell Physiol* 1990;143:213-21.
356. Chawla A, Lazar MA. Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. *Proc Natl Acad Sci USA* 1994;91:1786-90.
357. Batzer R, Liu Y, Cochran DL, Szmuckler-Moncler S, Dean DD, Boyan BD, *et al.* Prostaglandins mediate the effects of titanium surface roughness on MG63 osteoblast-like cells and alter cell responsiveness to $1\alpha,25\text{-(OH)}_2\text{D}_3$. *J Biomed Mater Res* 1998;41:489-96.
358. Zhi J, Sommerfeldt DW, Rubin CT, Hadjiargyrou M. Differential expression of neuroleukin in osseous tissues and its involvement in mineralization during osteoblast differentiation. *J Bone Miner Res* 2001;16:1994-2004.
359. Beck GR. Inorganic phosphate as a signaling molecule in osteoblast differentiation. [Review]. *J Cell Biochem* 2003;90:234-43.
360. Bellows CG, Heersche JN, Aubin JE. Inorganic phosphate added exogenously or released from beta-glycerophosphate initiates mineralization of osteoid nodules *in vitro*. *Bone Miner* 1992;17:15-29.
361. Lincks J, Boyan BD, Blanchard CR, Lohmann CH, Liu Y, Cochran DL, *et al.* Response of MG63 osteoblast-like cells to titanium and titanium alloy is dependent on surface roughness and composition. *Biomaterials* 1998;19:2219-32.
362. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, *et al.* Terminal osteoblast differentiation, mediated by runx2 and p27^{KIP1}, is disrupted in osteosarcoma. *J Cell Biol* 2004;167:925-34.
363. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Effects of biphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E₂ synthesis in the clonal osteoblast-like cell line MC3T3-E1. *Prostaglandins Leukot Essent Fatty Acids* 1997;56:121-5.
364. Isogai Y, Akatsu T, Ishizuya T, Yamaguchi A, Hori M, Takahashi N, *et al.* Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. *J Bone Miner Res* 1996;11:1384-93.
365. Shin C, Kim S, Her S, Kim D, Kim S. Ectopic overexpression of adipogenic transcription factors induces transdifferentiation of MC3T3-E1 osteoblasts. *Bone* 2005;36:S286.

366. Fukushima H, Jimi E, Okamoto F, Motokawa W, Okabe K. IL-1-induced receptor activator of NF- κ B ligand in human periodontal ligament cells involves ERK-dependent PGE₂ production. *Bone* 2005;36:267-75.
367. Jacobson A, Johansson S, Branting M, Melhus H. Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. *Biochem Biophys Res Commun* 2004;322:162-7.
368. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, *et al.* Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms in glucocorticoid-induced osteoporosis. *Endocrinology* 1999;140:4382-9.
369. Wu X, Pan G, McKenna MA, Zayzafoon M, Xiong W-C, McDonald JM. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. *J Bone Miner Res* 2005;20:107-16.
370. Viereck V, Gründker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. *J Cell Biochem* 2002;84:725-35.
371. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, *et al.* Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. *Biochem Biophys Res Commun* 1998;247:610-5.
372. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. *J Bone Miner Res* 2001;16:348-60.
373. Mollard RC, Kovacs HR, Fitzpatrick-Wong SC, Weiler HA. Low levels of dietary arachidonic acid and docosahexaenoic acid improve bone mass in neonatal piglets, but higher levels provide no benefit. *J Nutr* 2005;135:505-12.
374. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers: an overview of their protective roles in catabasis. *Prostaglandins Other Lipid Mediat* 2004;73:155-72.
375. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burggess T, *et al.* Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998;93:165-76.

376. Brändström H, Jonsson KB, Ohlsson C, Vidal O, Ljunghall S, Ljunggren O. Regulation of osteoprotegerin mRNA levels by prostaglandin E₂ in human bone marrow stroma cells. *Biochem Biophys Res Commun* 1998;247:338-41.
377. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. *Endocrinology* 2000;141:4768-76.
378. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, *et al.* RANKL expression is related to the differentiation state of human osteoblasts. *J Bone Miner Res* 2003;18:1088-98.
379. Ono K, Kaneko H, Choudhary S, Pilbeam CC, Lorenzo JA, Akatsu T, *et al.* Biphasic effect of prostaglandin E₂ on osteoclast formation in spleen cell cultures: role of the EP2 receptor. *J Bone Miner Res* 2005;20:23-9.
380. Eghbali-Fatourehchi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. *J Clin Invest* 2003;111:1221-30.

Addendum I

List of congresses where parts of the work were presented

1. Coetzee M, Kruger MC
Arachidonic acid and bone active hormone induce prostaglandin E₂ synthesis in osteoblasts.
Presentation: 10th Bone and Mineral Meeting, SEMDSA, Sandton, April 2001.
2. Coetzee M, Kruger MC
Arachidonic acid and bone active hormone induce prostaglandin E₂ synthesis in osteoblasts.
Presentation: New Zealand Endocrine Society Meeting, Wellington, May 2001.
3. Coetzee M, Kruger MC
Arachidonic acid and bone active hormone induce prostaglandin E₂ synthesis in osteoblasts.
Presentation: Study group, Department of Internal Medicine, University of Uppsala, Sweden, June 2002.
4. Coetzee M, Haag M, Kruger MC
The effects of essential fatty acids and oestrogen on the secretion of osteoprotegerin, a novel bone protective protein, by osteoblasts.
Poster: Faculty of Health Sciences, Faculty day, University of Pretoria, August 2003.
5. Coetzee M, Haag M, Kruger MC
The effects of essential fatty acids and oestrogen on the secretion of osteoprotegerin, a novel bone protective protein, by osteoblasts.
Poster: 31st Annual Congress of the Physiology Society of Southern Africa, Potchefstroom, September 2003.
6. Coetzee M, Haag M, Kruger MC
Exposure of MC3T3-E1 osteoblasts to polyunsaturated fatty acids modulates prostaglandin E₂ synthesis and secretion of osteoprotegerin.
Poster: 12th National Osteoporosis Foundation Symposium, SEMDSA, Sandton, 9-12 April 2005.
7. Coetzee M, Haag M, Kruger MC
Exposure of MC3T3-E1 osteoblast-like cells to arachidonic acid and docosahexaenoic acid modulates prostaglandin synthesis and secretion of osteoprotegerin.
Poster: 2nd Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, Geneva, Switzerland, 25-29 June 2005.

Addendum II

List of abstracts and articles published from this work

1. Coetzee M, Kruger MC
Arachidonic acid and bone active hormone induce prostaglandin E₂ synthesis in osteoblasts.
Abstract: JEMDSA 2001; 6:22.
2. Coetzee M, Kruger MC
Arachidonic acid and bone active hormone induce prostaglandin E₂ synthesis in osteoblasts.
Abstract: The Endocrine Society of Australia proceeding 2001; abstract 15, p 32.
3. Coetzee M, Kruger MC
Osteoprotegerin-Receptor Activator of Nuclear Factor- κ B Ligand ratio: a new approach to osteoporosis treatment? [Review].
Southern Medical Journal 2004;97:506-11.
4. Coetzee M, Haag M, Kruger MC
Exposure of MC3T3-E1 osteoblasts to polyunsaturated fatty acids modulates prostaglandin E₂ synthesis and secretion of osteoprotegerin.
Abstract: JEMDSA 2005;10:35-6.
5. Coetzee M, Haag M, Kruger MC
Exposure of MC3T3-E1 osteoblast-like cells to arachidonic acid and docosahexaenoic acid modulates prostaglandin synthesis and secretion of osteoprotegerin.
Abstract: Bone 2005;36:S276.
6. Coetzee M, Haag M, Claassen N, Kruger MC
Stimulation of prostaglandin E₂ (PGE₂) production by arachidonic acid, oestrogen and parathyroid hormone in MG-63 and MC3T3-E1 osteoblast-like cells.
Prostaglandins, Leukotrienes and Essential Fatty Acids 2005;76:423-430.